Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial

BACKGROUND: and objectives The Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 study demonstrated a significant beneficial effect of the vasopressin V2 receptor antagonist tolvaptan on rates of kidney growth and eGFR decline in autosom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin J Am Soc Nephrol
Main Authors: Torres, Vicente E., Higashihara, Eiji, Devuyst, Olivier, Chapman, Arlene B., Gansevoort, Ronald T., Grantham, Jared J., Perrone, Ronald D., Ouyang, John, Blais, Jaime D., Czerwiec, Frank S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4858477/
https://ncbi.nlm.nih.gov/pubmed/26912543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06300615
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados